5-((3-Amidobenzyl)oxy)nicotinamides as SIRT2 Inhibitors: A Study of Constrained Analogs

Teng Ai; Daniel Wilson; Liqiang Chen

doi:10.3390/molecules28227655

5-((3-Amidobenzyl)oxy)nicotinamides as SIRT2 Inhibitors: A Study of Constrained Analogs

Teng Ai, Daniel Wilson, Liqiang Chen

Center for Drug Design

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

SIRT2 is a member of NAD⁺-dependent sirtuins and its inhibition has been proposed as a promising therapeutic approach for treating human diseases, including neurodegenerative diseases, cancer, and infections. Expanding SIRT2 inhibitors based on the 3-aminobenzyloxy nicotinamide core structure, we have synthesized and evaluated constrained analogs and selected stereoisomers. Our structure-activity relationship (SAR) study has revealed that 2,3-constrained (S)-isomers possess enhanced in vitro enzymatic inhibitory activity against SIRT2 and retain excellent selectivity over SIRT1 and SIRT3, provided that a suitable ring A is used. This current study further explores SIRT2 inhibitors based on the 3-aminobenzyloxy nicotinamide scaffold and contributes to the discovery of potent, selective SIRT2 inhibitors that have been actively pursued for their potential therapeutic applications.

Original language	English (US)
Article number	7655
Journal	Molecules
Volume	28
Issue number	22
DOIs	https://doi.org/10.3390/molecules28227655
State	Published - Nov 2023

Bibliographical note

Publisher Copyright:
© 2023 by the authors.

Keywords

constrained inhibitors
SIRT1
SIRT2
SIRT3
sirtuin inhibitors
sirtuins

PubMed: MeSH publication types

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.3390/molecules28227655

OpenUrl availability

Full text

Cite this

@article{a13dc99793554ad1b9f457e6b9d96e89,

title = "5-((3-Amidobenzyl)oxy)nicotinamides as SIRT2 Inhibitors: A Study of Constrained Analogs",

abstract = "SIRT2 is a member of NAD+-dependent sirtuins and its inhibition has been proposed as a promising therapeutic approach for treating human diseases, including neurodegenerative diseases, cancer, and infections. Expanding SIRT2 inhibitors based on the 3-aminobenzyloxy nicotinamide core structure, we have synthesized and evaluated constrained analogs and selected stereoisomers. Our structure-activity relationship (SAR) study has revealed that 2,3-constrained (S)-isomers possess enhanced in vitro enzymatic inhibitory activity against SIRT2 and retain excellent selectivity over SIRT1 and SIRT3, provided that a suitable ring A is used. This current study further explores SIRT2 inhibitors based on the 3-aminobenzyloxy nicotinamide scaffold and contributes to the discovery of potent, selective SIRT2 inhibitors that have been actively pursued for their potential therapeutic applications.",

keywords = "constrained inhibitors, SIRT1, SIRT2, SIRT3, sirtuin inhibitors, sirtuins",

author = "Teng Ai and Daniel Wilson and Liqiang Chen",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = nov,

doi = "10.3390/molecules28227655",

language = "English (US)",

volume = "28",

journal = "Molecules",

issn = "1420-3049",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "22",

}

TY - JOUR

T1 - 5-((3-Amidobenzyl)oxy)nicotinamides as SIRT2 Inhibitors

T2 - A Study of Constrained Analogs

AU - Ai, Teng

AU - Wilson, Daniel

AU - Chen, Liqiang

PY - 2023/11

Y1 - 2023/11

N2 - SIRT2 is a member of NAD+-dependent sirtuins and its inhibition has been proposed as a promising therapeutic approach for treating human diseases, including neurodegenerative diseases, cancer, and infections. Expanding SIRT2 inhibitors based on the 3-aminobenzyloxy nicotinamide core structure, we have synthesized and evaluated constrained analogs and selected stereoisomers. Our structure-activity relationship (SAR) study has revealed that 2,3-constrained (S)-isomers possess enhanced in vitro enzymatic inhibitory activity against SIRT2 and retain excellent selectivity over SIRT1 and SIRT3, provided that a suitable ring A is used. This current study further explores SIRT2 inhibitors based on the 3-aminobenzyloxy nicotinamide scaffold and contributes to the discovery of potent, selective SIRT2 inhibitors that have been actively pursued for their potential therapeutic applications.

AB - SIRT2 is a member of NAD+-dependent sirtuins and its inhibition has been proposed as a promising therapeutic approach for treating human diseases, including neurodegenerative diseases, cancer, and infections. Expanding SIRT2 inhibitors based on the 3-aminobenzyloxy nicotinamide core structure, we have synthesized and evaluated constrained analogs and selected stereoisomers. Our structure-activity relationship (SAR) study has revealed that 2,3-constrained (S)-isomers possess enhanced in vitro enzymatic inhibitory activity against SIRT2 and retain excellent selectivity over SIRT1 and SIRT3, provided that a suitable ring A is used. This current study further explores SIRT2 inhibitors based on the 3-aminobenzyloxy nicotinamide scaffold and contributes to the discovery of potent, selective SIRT2 inhibitors that have been actively pursued for their potential therapeutic applications.

KW - constrained inhibitors

KW - SIRT1

KW - SIRT2

KW - SIRT3

KW - sirtuin inhibitors

KW - sirtuins

UR - http://www.scopus.com/inward/record.url?scp=85177767814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85177767814&partnerID=8YFLogxK

U2 - 10.3390/molecules28227655

DO - 10.3390/molecules28227655

M3 - Article

C2 - 38005376

AN - SCOPUS:85177767814

SN - 1420-3049

VL - 28

JO - Molecules

JF - Molecules

IS - 22

M1 - 7655

ER -

5-((3-Amidobenzyl)oxy)nicotinamides as SIRT2 Inhibitors: A Study of Constrained Analogs

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this